Remove tag drug-pricing
article thumbnail

Biogen’s Alzheimer’s drug: What’s the price tag on hope?

World of DTC Marketing

SUMMARY: The FDA is coming under intense pressure to approve Biogen’s Alzheimer’s drug, but Aaron S. ” For Biogen, the stakes are high as approval is likely to earn tens of millions, of to billions, in profits but is hope a reason to approve a drug over science? .” Biogen needs a new drug revenue badly.

article thumbnail

Orchard sets new gene therapy price tag at $4.25M—the steepest of any drug in the US

Fierce Pharma

Kyowa Kirin and its subsidiary Orchard Therapeutics have broken new boundaries in pricing, too. After scoring an FDA nod Monday for the first gene therapy to treat the rare genetic disease metachromatic leukodystrophy (MLD) in the U.S.,

FDA 288
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Amylyx ALS drug draws criticism over $158,000 price tag

pharmaphorum

Amylyx Pharmaceuticals’ Relyvrio – a new treatment for amyotrophic lateral sclerosis (ALS) approved by the FDA on Thursday, after review of the data from its phase 2 trial – was the next day set at a list price of $158,000 per year in the US, sparking outcry. ALS affects over 30,000 people in the US.

article thumbnail

Sanders takes aim at US drug prices of Novo’s Ozempic and Wegovy

Pharmaceutical Technology

A Senate Committee is investigating the “outrageously high” US price tags of the blockbuster diabetes and obesity drugs.

52
article thumbnail

Healthcare doesn’t give a damn about patients

World of DTC Marketing

A new analysis released Wednesday by Patients for Affordable Drugs estimates that pharmaceutical companies in the U.S. have raised drug prices 1,186 times so far this year. Patients for Affordable Drugs found that between June 24 and July 5, pharmaceutical companies increased prices for 133 products.

article thumbnail

Novartis pays $100M to get Mallinckrodt’s ticket for a speedier FDA drug review

MedCity News

The $100 million price tag is in the neighborhood of the going rate for these vouchers, which grant a company a shorter regulatory review timeline for a drug that addresses a rare or neglected disease. Novartis is acquiring an FDA priority review voucher from Mallinckrodt Pharmaceuticals.

FDA 109
article thumbnail

Medicare savings won’t make a dent in healthcare costs

World of DTC Marketing

SUMMARY: Allowing Medicare to negotiate drug prices is popular with voters because the media has been focused on the high price of some drugs, but this measure won’t lead to lower healthcare costs. If pharma is a business, they will find a way to develop, buy, or acquire new drugs. healthcare.